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Gembloux, BelgiumAbstractInfectious diarrhoea ranks among the leading causes of morbidity worldwide. Although most acute diarrhoeal episodes are self-limiting, the
diagnosis and treatment of persistent diarrhoea (2 weeks) are cumbersome and require laboratory identiﬁcation of the causative pathogen.
Stool-based PCR assays have greatly improved the previously disappointing pathogen detection rates in high-income countries, but there is a
paucity of quality data from tropical settings. We performed a case–control study to elucidate the spectrum of intestinal pathogens in patients
with persistent diarrhoea and asymptomatic controls in southern Côte d’Ivoire. Stool samples from 68 patients and 68 controls were
obtained and subjected to molecular multiplex testing with the Luminex® Gastrointestinal Pathogen Panel (GPP), microscopy and rapid
antigen detection tests for the diagnosis of diarrhoeagenic pathogens. Overall, 20 different bacteria, parasites and viruses were detected
by the suite of diagnostic methods employed. At least one pathogen was observed in 84% of the participants, and co-infections were
observed in >50% of the participants. Enterotoxigenic Escherichia coli (32%), Giardia intestinalis (29%) and Shigella species (20%) were the
predominant pathogens, and Strongyloides stercoralis (10%) was the most prevalent helminth. Pathogen frequencies and numbers of co-
infections were similar in patients and controls. Although the Luminex® GPP detects a broad range of pathogens, microscopy for
helminths and intestinal protozoa remains necessary to cover the full aetiological spectrum in tropical settings. We conclude that highly
sensitive multiplex PCR assays constitute a useful screening tool, but that positive results might need to be conﬁrmed by independent
methods to discriminate active infection from asymptomatic faecal shedding of nucleic acids.
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common contributor to the global burden of disease, ac-
counting for a burden of 89.5 million disability-adjusted life-
years [1]. Low-income and middle-income countries areClin Microbiol Infect 2015; 21: 591.e1–591.e10
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three leading causes of mortality in children under the age of 5
years [2,3]. The aetiology of diarrhoea, abdominal pain and
related digestive disorders may include >40 infectious patho-
gens, which can be grouped into bacteria, parasites (helminths
and intestinal protozoa), and viruses [4]. Although many diar-
rhoeal episodes are self-limiting and of only light or moderate
severity, a considerable proportion of patients may develop
either severe acute disease or long-lasting symptoms such as
persistent diarrhoea (duration: 2 weeks) [5]. Differentiation
between several aetiological agents based on clinical presenta-
tion alone is difﬁcult and error-prone. Hence, laboratory ex-
aminations are important to identify the causative agents of
infectious diarrhoeal diseases. However, no currently available
laboratory technique can diagnose the many potentially impli-
cated pathogens with high accuracy. It follows that detection
rates of intestinal pathogens are disappointing if conventional
diagnostic methods are employed and only a narrow spectrum
of pathogens is targeted. Prior research has shown that the
causative infectious agent may remain undetected in up to 80%
of stool samples obtained from patients with diarrhoea [6].
The development of molecular diagnostic methods, such as
PCR assays, has considerably increased the diagnostic sensitivity
for the detection of many intestinal pathogens [7]. Recently,
several multiplex PCR panels that may detect multiple diar-
rhoeagenic pathogens concurrently in a single stool sample have
become available, and they improve the diagnostic yield in
symptomatic patients with digestive disorders. The Luminex®
xTAG Gastrointestinal Pathogen Panel (GPP; Luminex® Cor-
poration, Austin, TX, USA) is a technique that uses ﬂuorescent
beads to allow for the concurrent detection of 15 pathogens:
nine bacteria, three viruses, and three intestinal protozoa [8].
The Luminex® GPP is licensed for use in the USA, Canada, and
Europe, where it is being increasingly employed in hospitals
[9,10] and travel clinics for the diagnosis of acute diarrhoea
[11,12]. So far, however, experience with a multiplex Luminex®
platform for the diagnosis of intestinal pathogens in the tropics
is scant. Additionally, it remains to be elucidated how this
multiplex assay performs if applied to stool specimens from
asymptomatic individuals, especially in settings of high ende-
micity, where multiple pathogens are the norm rather than the
exception. It is conceivable that a combination of different
diagnostic tests may lead to more accurate results [13]. Most
commercially available multiplex PCR assays do not cover an
extensive panel of parasitic pathogens, despite the fact that
these are considered to be important causative agents of
diarrhoeal diseases in the tropics [4]. Thus, a combination of
diagnostic methods has been proposed for the comprehensive
assessment of diarrhoea and related digestive disorders in such
settings.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectHere, we report ﬁndings from a study that employed a suite
of diagnostic methods, including the Luminex® GPP, parasito-
logical microscopic examinations, and rapid antigen detection
tests, for a detailed diagnostic work-up of patients presenting
with persistent diarrhoea. The study was carried out in the
southern part of Côte d’Ivoire towards the end of 2012, and
also included asymptomatic controls.Materials and methodsEthics statement
Individuals aged 12 months with residency in Dabou, south-
ern Côte d’Ivoire who had provided written informed consent
(parents/guardians signed for individuals aged <18 years) were
eligible to participate. Study approval was given by the institu-
tional research commissions of the Swiss Tropical and Public
Health Institute (Basel, Switzerland), the Centre Suisse de
Recherches Scientiﬁques en Côte d’Ivoire (Abidjan, Côte
d’Ivoire), and the Directorate of the Hôpital Méthodiste in
Dabou. The study is registered in Current Controlled Trials
(identiﬁer: ISRCTN86951400). Within 2 days of enrolment,
study participants were informed about their individual diag-
nostic test results based on microscopic analysis of stool sam-
ples and rapid diagnostic tests (RDTs). In the case of a parasitic
infection, free treatment was offered, i.e. albendazole (400 mg)
against soil-transmitted helminths, ivermectin (200 μg/kg)
against Strongyloides stercoralis, praziquantel (40 mg/kg) against
Schistosoma mansoni, and metronidazole against symptomatic
Giardia intestinalis (400 mg three times daily for 5–7 days).
Because the PCR tests were conducted several weeks after
enrolment of study subjects in a reference laboratory abroad,
these results did not guide the clinical management of infected
individuals.
Study location, design, and population
Our exploratory study was part of a multi-country assessment
to identify suitable settings for a subsequent prospective, non-
experimental case–control study to be implemented in four
countries. The purpose of the current investigation was to
deepen our understanding of the aetiology and clinical pre-
sentations of persistent digestive disorders in the prospective
study site in Côte d’Ivoire. The research is coordinated by the
European research network with the acronym NIDIAG, which
aims to develop simple and cost-effective diagnostic–treatment
algorithms for three clinical syndromes (i.e. persistent digestive
disorders [4], persistent fever [14] and neurological disorders
[15]) in tropical settings.
The current study was carried out over a 2-week period in
October 2012 in Dabou, a small town in south Côte d’Ivoire,ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 591.e1–591.e10
CMI Becker et al. PCR and microscopy for diarrhoeal pathogens 591.e3and 11 surrounding villages belonging to the same health district.
The study area is located ~30 km west of Abidjan, the economic
capital of Côte d’Ivoire. Individuals aged 12 months presenting
with persistent diarrhoea were eligible to participate. Recom-
mendations put forth by the World Health Organization
(WHO) were used to deﬁne persistent diarrhoea, i.e. three or
more loose or liquid stools per day for any period lasting for 2
weeks [16]. Individuals with acute diarrhoea or other abdominal
symptoms with a duration of <2 weeks were excluded.
Training sessions were held with physicians from the local
study hospital (Hôpital Méthodiste de Dabou) and with nurses
from the surrounding village health are centres. The healthcare
professionals were invited to identify eligible patients and to
inform them about the purpose and procedures of the study.
Additionally, medical personnel from the village healthcare
centres were trained in obtaining written informed consent and
ﬁlling in a short, pretested clinical questionnaire.
To allow for comparison of pathogen detection frequencies
between symptomatic and asymptomatic individuals, a case–
control design was adopted. Hence, individuals without any
gastrointestinal complaints within the preceding 2 months were
also invited to participate, and were used as controls. These
controls were randomly selected from the same study area, and
were matched to the cases by age group (1–5 years, 6–15
years, 16–25 years, 26–45 years, and >45 years) and village of
residency (frequency matching).
Field and laboratory procedures
Stool collection containers were distributed by healthcare
professionals, and participating individuals provided one fresh
morning stool sample, which was transferred to the local
hospital laboratory in Dabou. On the day of collection, the
stool samples were examined microscopically by two senior
laboratory technicians for the presence of a broad range of
parasitic infections. Speciﬁcally, the following tests were
employed: the Kato–Katz method (duplicate Kato–Katz thick
smears for the diagnosis of S. mansoni and soil-transmitted
helminths); the formalin–ether concentration technique
(FECT) (for the diagnosis of helminths and intestinal protozoa);
and Baermann funnel concentration and Koga agar plate culture
(for the diagnosis of S. stercoralis and hookworm). Additionally,
for the diagnosis of G. intestinalis and Cryptosporidium species, an
antigen detection RDT was employed (Crypto/Giardia Duo-
Strip; Coris BioConcept, Gembloux, Belgium). At the time of
the study, the performance of bacterial stool culture was
logistically not feasible at Dabou hospital.
Molecular post-hoc testing
From each stool sample, ~300 mg was placed in a vial and
stored in a refrigerator (4°C). However, the cold chain couldClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infnot be maintained consistently, owing to an irregular power
supply, which is common in many parts of Côte d’Ivoire. Within
8–19 days, the samples were transferred to Homburg, Ger-
many for further processing with the commercial Luminex®
GPP. This assay concurrently detects nucleic acids from nine
different bacteria (i.e. Campylobacter species, Clostridium difﬁcile,
Escherichia coli O107, enterotoxigenic E. coli (ETEC), Shiga-toxin
producing E. coli, Salmonella species, Shigella species, Vibrio
species, and Yersinia enterocolitica), three viruses (adenovirus,
norovirus GI/II, and rotavirus), and three intestinal protozoa
(Cryptosporidium species, E. histolytica, and G. intestinalis). Note
that no helminths are included in the current Luminex® GPP.
Nucleic acid extraction of ~100 mg of each stool sample was
performed with an automated puriﬁcation system (Maxwell 16
instrument with tissue LEV DNA puriﬁcation kit; Promega,
Madison, WI, USA). All samples were spiked with 2 μL of in-
ternal control (MS2, a bacteriophage) before puriﬁcation.
Extracted nucleic acids were eluted into a ﬁnal volume of 75 μL.
PCR, hybridisation reactions and data analysis were carried out
according to the manufacturer’s instructions. In brief, 15 μL of a
master mix (2.5 μL of RNAse-free water, 7.5 μL of buffer,
0.5 μL of bovine serum albumin (10 mg/mL), 2.5 μL of GPP
primer mix, and 2.0 μL of enzyme mix) was mixed with 10 μL
of each extracted sample and subjected to multiplex reverse
transcriptase (RT-)PCR in a preheated thermal cycler (53°C).
The RT-PCR programme was performed as previously
described [17]. Negative and positive controls were included in
each PCR run. The PCR products were mixed with the
manufacturer-provided ﬂuorescent bead mix, and a hybrid-
isation reaction was performed in the thermal cycler (3 min at
60°C, followed by 45 min at 45°C). Samples were then trans-
ferred into the Magpix detection system. Data analysis was
carried out with xTAG Data Analysis Software.
Clinical questionnaire
Study participants were interviewed with a pretested ques-
tionnaire to obtain baseline demographic information (age, sex,
and residency) and to document self-reported clinical
morbidity, such as the current (e.g. duration of symptoms and
speciﬁc complaints) and past (e.g. antibiotic and antiparasitic
treatment, and pre-existing morbidities) medical history.
Questionnaires were administered by trained medical
personnel.
Statistical analysis
Data were double-entered and cross-checked with Microsoft
Excel version 14.0 (edition 2010; Microsoft Corporation).
Statistical analysis was performed with STATA version 12.0
(StataCorp., College Station, TX, USA). In the absence of a
‘true’ diagnostic reference standard, a positive test result in anyectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 591.e1–591.e10
TABLE 1. Epidemiological characteristics of 136 study
participants in Dabou, south Côte d’Ivoire, examined in
October 2012
Total, n
Patients with
persistent
diarrhoea, n
Asymptomatic
controls, n pa
Sex
Female 66 36 30
Male 70 32 38 0.303
Age group (years)
1–5 37 22 15
6–15 13 5 8
16–25 14 7 7
26–45 43 17 26
>45 29 17 12 0.313
Residency
Urban (Dabou) 25 10 15
Rural (surrounding
villages)
111 58 53 0.268
aDerived from Pearson’s χ2-test.
591.e4 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIof the employed diagnostic tests was considered to be a ‘true
positive’, thus leading to a combination of all positive test re-
sults for a certain pathogen being the internal diagnostic
reference standard in this study.
The prevalence of each pathogen was determined on the
basis of the combination of the available diagnostic tests, and
differences regarding the frequency in symptomatic vs. asymp-
tomatic patients were assessed with Pearson’s χ2-test or
Fisher’s exact test, as appropriate. More than one diagnostic
test was employed for the detection of Cryptosporidium species,
E. histolytica, and G. intestinalis. Sensitivity, negative predictive
value and corresponding 95% conﬁdence intervals (CIs) were
calculated for every single technique in relation to the diag-
nostic reference standard, and the diagnostic accuracies of the
different methods were compared. A p-value of <0.05 was
considered to indicate statistical signiﬁcance. In the absence of a
reference standard indicating the number of ‘true-negative’ and
‘false-positive’ samples, no speciﬁcity or positive predictive
value could be calculated. The agreement between different
diagnostic methods was evaluated with Cohen’s kappa measure
(κ) [18]. Univariate odds ratios (ORs) were computed to
analyse signiﬁcant associations between self-reported gastroin-
testinal symptoms and infection with a speciﬁc pathogen.ResultsStudy cohort
Stool samples from 335 individuals were examined: 71 speci-
mens from patients with persistent diarrhoea, and 264 from
asymptomatic controls. The quantity of stool was sufﬁcient for
the performance of molecular post-hoc testing on 68 patient
samples. Subsequently, 68 residency-matched and age group-Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectmatched asymptomatic controls were selected. Hence, our
ﬁnal study sample consisted of 136 individuals. In terms of age
range, sex, and parasite spectrum (according to microscopy),
the 68 stool samples selected among the 264 controls for post-
hoc molecular analysis were comparable to those control
specimens that were not further analysed (n = 196).
In the ﬁnal study sample, there were slightly more males
(51%, n = 70) than females (49%, n = 66), and most of the
participants lived in villages surrounding the town of Dabou
(82%, n = 111). The epidemiological characteristics of symp-
tomatic patients and asymptomatic controls are shown in
Table 1.
Bacterial, parasitic, and viral infections
At least one intestinal infection was diagnosed in 84% (n = 114)
of all study participants. Intestinal protozoa (68%, n = 93) and
bacterial (51%, n = 69) infections were far more prevalent than
helminth (17%, n = 23) and viral (9%, n = 12) infections. Overall,
20 different species of intestinal pathogens were detected. The
predominant infectious agents were ETEC (32%, n = 43),
Entamoeba coli (29%, n = 40), G. intestinalis (29%, n = 39), and
Shigella species (20%, n = 27). Larvae of S. stercoralis were found
in 14 people (10%), and constituted the predominant helminth
species.
Table 2 shows the prevalence of all detected bacteria, par-
asites and viruses, and their frequencies in patients and con-
trols. Shigella species were found more often in patients than in
asymptomatic controls (27% vs. 13%; p 0.053). On the other
hand, Endolimax nana (7% vs. 32%; p 0.001) and E. coli O157 (0%
vs. 6%; p 0.042) were signiﬁcantly more common in asymp-
tomatic controls. As shown in Fig. 1, infection rates of some
intestinal pathogens were somewhat higher in rural villages
located in the west of the study area (e.g. ETEC; 47% in villages
located 10 km west from Dabou vs. 33% in the town of Dabou),
but the difference lacked statistical signiﬁcance.
Co-infections
Co-infections were common. Infections with at least two in-
testinal pathogen species were diagnosed in 37 patients (54%)
and in 47 asymptomatic controls (69%). In two individuals with
persistent diarrhoea, a concurrent infection with up to six
different gastrointestinal pathogens was diagnosed. Fig. 2 sum-
marises the occurrence of co-infections in patients and
controls.
Combined diagnostic approaches
The combination of multiplex PCR, microscopy, and RDTs
detected more pathogens than any of the three techniques
alone. The pathogen detection rates in symptomatic patients
were 69% for multiplex PCR, 56% for microscopy, and 16% forious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 591.e1–591.e10
TABLE 2. Prevalence of intestinal pathogens (helminths, intestinal protozoa, bacteria, and viruses) in 136 individuals in Dabou, south Côte d’Ivoire, in October 2012, as assessed
with different diagnostic techniques
Diagnostic technique(s)
All participants Symptomatic patients Asymptomatic controls
paN % 95% CI N % N %
Helminths
Strongyloides stercoralis Microscopy 14 10 5–16 8 12 6 9 0.573
Hookworm Microscopy 10 7 3–12 5 7 5 7 1.000
Ascaris lumbricoides Microscopy 2 2 0.01–4 2 3 0 0 0.248
Intestinal protozoa
Entamoeba coli Microscopy 40 29 22–37 18 27 22 32 0.452
Giardia intestinalis Microscopy, RDT, PCR 39 29 21–36 18 27 21 31 0.569
Endolimax nana Microscopy 27 20 13–27 5 7 22 32 0.001
Blastocystis spp. Microscopy 13 10 5–15 4 6 9 13 0.145
Chilomastix mesnili Microscopy 13 10 5–15 9 13 4 6 0.145
Cryptosporidium spp. RDT, PCR 12 9 4–14 3 4 9 13 0.070
Iodamoeba bütschlii Microscopy 6 4 0.9–8 3 4 3 4 1.000
Entamoeba histolytica/E. disparb Microscopy, PCR 5 4 0.5–7 1 2 4 6 0.183
Entamoeba hartmanni Microscopy 1 1 0.01–2.2 0 0 1 2 0.500
Bacteriac
Enterotoxigenic Escherichia coli PCR 43 32 24–40 23 34 20 29 0.580
Shigella spp. PCR 27 20 13–27 18 27 9 13 0.053
Campylobacter spp. PCR 12 9 4–14 4 6 8 12 0.227
Salmonella spp. PCR 9 7 2–11 5 7 4 6 0.730
Escherichia coli O157 PCR 4 3 0.07–6 0 0 4 6 0.042
Viruses
Norovirus GI/GII PCR 9 7 2–11 6 8 3 4 0.246
Adenovirus 40/41 PCR 2 2 0.01–4 1 2 1 2 1.000
Rotavirus A PCR 1 1 0.01–2 1 2 0 0 0.500
RDT, rapid diagnostic test.
aDerived from Pearson’s χ2-test or Fisher’s exact test, as appropriate.
bMicroscopy is not able to differentiate between Entamoeba histolytica and the apathogenic Entamoeba dispar. In this study, three of the ﬁve positive samples were detected by microscopy, but gave a negative PCR test result, and so most likely
constituted an infection with E. dispar.
cNone of the following bacterial pathogens targeted by the Luminex® GPP were detected: toxigenic Clostridium difﬁcile, Shiga-toxin producing Escherichia coli, Vibrio cholerae, and Yersinia enterocolitica.
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FIG. 1. Spatial distribution of selected gastrointestinal infections in 136 individuals from Dabou and surrounding villages in southern Côte d’Ivoire.
ETEC, enterotoxigenic Escherichia coli.
591.e6 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIRDTs. A combination of all three methods identiﬁed at least
one pathogen in 84% of all stool samples (Fig. 3).
Comparison of different diagnostic methods
Among the three techniques employed for the diagnosis of
G. intestinalis (the Luminex® GPP, microscopy with the FECT,
and antigen detection with an RDT), the Luminex® PCR assay
showed the highest sensitivity (84.6%; 95% CI 69.5–94.1%) and
negative predictive value (94.2%; 95% CI 87.8–97.8%).
Considerably lower sensitivity was observed for the FECT and
the RDT, i.e. 51.3% and 40.0%, respectively. The latter two
techniques, however, identiﬁed an additional six infections that
remained undetected by the Luminex® PCR assay. The diag-
nostic agreement between microscopy and the RDT was sub-
stantial (κ = 0.64), whereas it was moderate if one of both
techniques was compared with PCR (microscopy and PCR,
κ = 0.47; RDT and PCR, κ = 0.46).
For the diagnosis of Cryptosporidium species, RDT results
were available for 121 of the 136 samples, and these were
compared with PCR. Only one of ten positive samples was
conﬁrmed by both methods, whereas the majority of infections
were exclusively detected by one single technique (PCR, n = 5;
RDT, n = 4). For E. histolytica detection, microscopy revealedClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectthree infections that were PCR-negative. However, care is
indicated, as microscopy does not allow distinction between
E. histolytica and the morphologically identical E. dispar [19].
PCR identiﬁed two E. histolytica-positive stool samples.
Questionnaire survey
Self-reported gastrointestinal morbidity was high among the 68
patients. Besides the main health complaint of persistent diar-
rhoea, abdominal pain and weight loss were commonly re-
ported (71% and 28%, respectively). Nausea was signiﬁcantly
associated with hookworm (OR 4.97, 95% CI 1.11–22.25) and
S. stercoralis (OR 5.02, 95% CI 1.31–19.25). Vomiting was
signiﬁcantly associated with Salmonella species (OR 5.85, 95%
CI 1.27–27.0). Intestinal colonisation with the apathogenic in-
testinal protozoon E. nana was inversely correlated with
persistent diarrhoea (OR 0.17, 95% CI 0.05–0.47) and
abdominal pain (OR 0.26, 95% CI 0.08–0.79).
Self-reported treatment
Previous treatment with anti-infective drugs was reported by
25% of the symptomatic patients (n = 17). Albendazole (n = 8)
was the most commonly used anthelminthic drug, followed by
pyrantel pamoate (n = 4), and mebendazole (n = 2).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 591.e1–591.e10
FIG. 2. Number of detected gastrointestinal infections in 136 in-
dividuals in Dabou and surrounding villages in southern Côte d’Ivoire,
stratiﬁed according to symptomatic patients and asymptomatic
controls.
FIG. 3. Pathogen detection rates in 68 patients with persistent diarrhoea a
southern Côte d’Ivoire, according to three different diagnostic methods (mult
diagnostic approach.
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Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfTrimethoprim–sulphamethoxazole (n = 10) and metronidazole
(n = 5) were the only antibiotics used. Combination therapy
with two different drugs was reported by 12 of 17 symptomatic
patients. In contrast, only two individuals without persistent
diarrhoea reported any anti-infective treatment within the
preceding 2 months (albendazole, n = 1; pyrantel pamoate,
n = 1).DiscussionDiarrhoea remains a major public health issue in low-income
and middle-income countries, and is caused by a variety of in-
testinal pathogens. Previous studies have shown that the com-
bination of several diagnostic methods for detection of
pathogens in the stool generates the most accurate results [13].
Recent advances in multiplex platforms have the potential to
increase sensitivity and to fast-track diagnostic testing, which in
turn deepens our understanding of the causal agents giving rise
to digestive disorders [20]. Here, we report the results after
application of a suite of diagnostic methods, including multiplex
PCR (Luminex® GPP, facilitating analysis of 15 differentnd 68 asymptomatic controls from Dabou and surrounding villages in
iplex PCR, microscopy, and rapid diagnostic test (RDT)) and a combined
ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 591.e1–591.e10
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ridium species and G. intestinalis), to determine the spectrum of
gastrointestinal pathogens in faecal samples of patients with
persistent diarrhoea and among age group-matched and
residency-matched asymptomatic controls from southern Côte
d’Ivoire. As compared with each diagnostic method alone, the
yield of the combined approach was considerable. Indeed, 11 of
15 pathogens targeted by our multiplex PCR were detected,
and stool microscopy identiﬁed an additional nine helminth and
intestinal protozoa species that are not diagnosed by the cur-
rent Luminex® GPP. Hence, a total of 20 different bacteria,
parasites and viruses were detected. More than 80% of the
participants—regardless of whether they were symptomatic or
asymptomatic—harboured at least one pathogen species, and
more than half of the participants were co-infected. Self-re-
ported gastrointestinal morbidity was high in patients with
persistent diarrhoea, and >80% of them lived in rural villages
surrounding the town of Dabou.
The accuracy of the Luminex® GPP for the diagnosis of
acute infectious gastroenteritis has been assessed previously in
various hospital settings in Europe [8,17,21,22] and the USA
[23–25]. As compared with conventional techniques or real-
time PCR assays, high sensitivity and speciﬁcity were re-
ported in symptomatic patients. However, the Luminex® GPP
has yet to be validated in the tropics, and no asymptomatic
individuals were examined with this platform in previous
studies. It is of note that a recent study from The Netherlands
reported an elevated number of false-positive results for the
detection of E. histolytica and Salmonella species [9]. The au-
thors concluded that a conﬁrmatory test might be necessary at
least for these two pathogens, because PCR alone does not
allow the distinction of active infection from asymptomatic
shedding of nucleic acids. New research conducted in a travel
clinic in Switzerland showed a pathogen detection rate of 11%
in returning travellers, with ETEC being the most commonly
identiﬁed organism [11]. Likewise, application of the Luminex®
GPP in a Spanish travel clinic revealed at least one pathogen in
36% of stool samples obtained from symptomatic travellers
returning from the tropics [12]. In the latter study, ETEC and
Shigella species were the most prevalent bacteria, and
G. intestinalis was the most common intestinal protozoon,
which is in line with our results from a tropical setting
(southern Côte d’Ivoire). In both European travel clinics, the
molecular assay signiﬁcantly improved the pathogen detection
rate, but not all PCR-positive results could be conﬁrmed with
independent reference tests (e.g. real-time PCR and bacterial
stool culture), and concerns about the suitability of nucleic
acid-based tests as a single method without conﬁrmatory tests
were therefore raised. Further limitations of the Luminex®
GPP for application in tropical settings include the high cost ofClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectthe reagents and the need for sophisticated laboratory
infrastructure.
Three issues emerge from the current study that are worth
discussing. First, 58 of 68 patients with persistent diarrhoea
were from villages within a 25-km radius of the town of
Dabou, where the study hospital is located. If the study had
not included village health centres, the true relevance of
persistent diarrhoea as a health problem in this part of
southern Côte d’Ivoire would have been underestimated.
Hence, this ﬁnding underlines the need to conduct clinical
studies in rural, remote areas to assess more accurately the
true burden of infectious diseases in tropical settings. Second,
co-infections were the norm rather than the exception, con-
ﬁrming prior research in Côte d’Ivoire [26]. The systematic
application of highly sensitive diagnostic assays (i.e. multiplex
PCR) has revealed that co-infections occur even in industri-
alised countries in a considerable proportion of patients with
diarrhoea [7]. Hence, the concept of one speciﬁc pathogen
causing digestive disorders is gradually being replaced by a
more complex understanding of the interactions between
several pathogens giving rise to diarrhoeal diseases [27]. Third,
the overall detection rates for most pathogens were similar
between symptomatic patients with persistent diarrhoea and
asymptomatic controls. This observation may be explained
either by asymptomatic colonisation or by prolonged nucleic
acid shedding in the absence of viable pathogens, e.g. following
a resolved infection. Whereas asymptomatic chronic in-
fections with intestinal parasites such as G. intestinalis or soil-
transmitted helminths commonly occur in endemic settings
[28], obligate pathogens such as Shigella are not considered to
asymptomatically colonise the gastrointestinal tract. It might
be speculated that the high analytical sensitivity of molecular
diagnostic assays may also result in the detection of ‘envi-
ronmental contamination’ by inactive pathogens, thus
rendering these techniques ‘too sensitive’ and leading to a high
rate of positive results even in the absence of active infection.
Hence, PCR may be used as a screening tool to sort out the
negative samples, but conﬁrmation of PCR-positive specimens
by microscopy or culture-based techniques might be neces-
sary to prove active, clinically relevant infections with vital
pathogens. Further research is needed to elucidate whether
the results produced by qualitative PCR assays, which merely
detect the presence of pathogen nucleic acids in stool speci-
mens, are sufﬁcient to guide therapeutic decision-making in
highly endemic areas where co-infections are common. In
contrast, it may be hypothesised that quantitative PCR assays
could be more useful in distinguishing ongoing infections from
‘environmental contamination’.
In addition to the Luminex® GPP, a combination of several
microscopic techniques revealed helminth infections in 17% ofious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 591.e1–591.e10
CMI Becker et al. PCR and microscopy for diarrhoeal pathogens 591.e9all study participants, predominantly caused by S. stercoralis and
hookworm. So far, however, no helminth species and only
three intestinal protozoa species are targeted by the Luminex®
GPP. Hence, our ﬁndings call for a combined diagnostic strategy
to comprehensively assess diarrhoea in the tropics and in travel
clinics, where soil-transmitted helminths and intestinal pro-
tozoa constitute important agents of digestive disorders [4,29].
Further development of the Luminex® GPP to broaden its
diagnostic range, speciﬁcally detection of helminth infections,
will enhance the suitability of this multiplex PCR assay for
application in tropical settings and travel clinics. A recently
published ‘cookbook’ might facilitate the development of such
setting-speciﬁc multiplex assays with the Luminex® technology
[30].
Our study has several limitations. First, for most pathogens
that are currently targeted by the Luminex® GPP, we did not
perform alternative reference diagnostic tests (e.g. bacterio-
logical stool culture) to assess the viability of the detected
pathogen. However, other studies have reported excellent
sensitivity and speciﬁcity for most pathogens that are included
in the current Luminex® GPP conﬁguration [8,23,25], and our
comparison of PCR, microscopy and RDTs for the detection
of G. intestinalis conﬁrms the superiority of the molecular assay
over other diagnostic methods [31]. However, we cannot
exclude the possibility that some PCR-positive results may
have been false-positives. Second, the prolonged storage of the
stool samples (up to 19 days) at 4°C before they were
transferred to a reference laboratory in Europe for post-hoc
molecular analysis may have negatively impacted on the PCR
results, as degradation of some pathogen nucleic acids might
have occurred. Third, even though we employed a suite of
diagnostic tests, some pathogens that are known to potentially
cause persistent diarrhoea might have been missed. The
additional use of, for example, acid-fast staining for detection
of Cyclospora cayetanensis could have detected further relevant
pathogens. Fourth, examination of more than one stool sample
would have been desirable for improved diagnosis of intestinal
parasites that are shed in the faeces with considerable day-to-
day variation [32]. Fifth, the number of examined stool sam-
ples in the current study was relatively small, thus hampering a
more rigorous assessment of the association between
perceived gastrointestinal morbidity and a distinct pathogen.
Sixth, morbidity in this study was exclusively assessed by self-
report, and no reproducible, standardised clinical examination
was performed to assess an individual’s health status. Some of
the aforementioned shortcomings will be addressed during a
larger multi-country study on persistent diarrhoea that is
currently being implemented in Côte d’Ivoire, Mali, and Nepal,
carried out by the NIDIAG research consortium (www.nidiag.
org).Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfConclusions and recommendationsA diagnostic strategy consisting of a sensitive multiplex PCR
assay in combination with parasitological microscopic tech-
niques and RDTs detected a broad range of bacteria, parasites,
and viruses in >80% of patients with persistent diarrhoea in
southern Côte d’Ivoire. However, correct diagnosis of the
clinically most signiﬁcant pathogens is hampered by co-
infections and surprisingly high detection rates of facultative
and obligate pathogens even in asymptomatic controls. Future
studies investigating persistent diarrhoea should adopt a case–
control design and attempt to quantify and compare the path-
ogen load between symptomatic and asymptomatic individuals.
The Luminex® GPP covers a wide range of diarrhoeagenic
pathogens, and may constitute a useful screening tool to rapidly
exclude common infectious agents. However, conﬁrmatory
methods may still be necessary in cases of PCR-positive results
to discriminate clinically relevant infections with viable patho-
gens from asymptomatic carriage or nucleic acid shedding after
resolved disease. In its current conﬁguration, the Luminex®
GPP does not detect helminth infections, which limits its suit-
ability as screening tool in the tropics and subtropics, where
helminthiases are still pervasive.Transparency declarationThe reagents for the Luminex® xTAG multiplex PCR and the
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